Financial Performance - Sales for the quarter were $67,167,000, an increase of 43.5% from $46,778,000 in the comparable period of the prior year[92] - Domestic sales for the quarter were $51,976,000, up 63.6% compared to $31,774,000 in the prior year[92] - Gross profit margin for the three months ended January 31, 2025 was 27.4%, up from 25.7% in the comparable quarter of the prior year[95] - Net earnings for the three months ended January 31, 2025 were $1,354,000, or $0.45 per diluted share, down from $2,521,000, or $0.85 per diluted share in the prior year[101] - Operating expenses for the three months ended January 31, 2025 were $16,129,000, or 24.0% of sales, compared to $8,223,000, or 17.6% of sales in the prior year[97] - The effective income tax rate for the three months ended January 31, 2025 was (8.5)%, compared to 27.9% for the same period in the prior year[99] Acquisition and Investments - The acquisition of Nu Aire was completed for $55.0 million, enhancing the company's capabilities and market presence[87] - The company used net cash of $30,385,000 in investing activities during the nine months ended January 31, 2025, primarily for the acquisition of Nu Aire[105] Order Backlog and Working Capital - The company's order backlog was $221.6 million at January 31, 2025, compared to $152.3 million at January 31, 2024[94] - The company had working capital of $58,441,000 at January 31, 2025, compared to $56,037,000 at April 30, 2024[103]
Kewaunee Scientific (KEQU) - 2025 Q3 - Quarterly Report